Fortress Biotech, Inc.

FBIO Healthcare Biotechnology

Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.

Revenue
+14.0%
EPS
−116.0%
Free cash flow
−115.4%
Total debt
−35.7%

Quarter to June 2026, against a year earlier

1.85 0.01 +0.54%
Market cap
$61.4M
P/E
0.6×
Fwd P/E
0.8×
Dividend yield
—
F-score
5/9
Altman Z
−5.47
Beneish M
−0.01
Dividend safety
20/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.73 0.94
P/S ratio
1.62 1.61 1.33 1.42
P/FCF ratio
0.00 0.00 0.74 1.13
P/Operating CF
(16.50) (8.14) 0.43 (1.64)
P/B ratio
1.55 1.64 0.43 0.47
EV/Sales
1.06 1.25 (1.92) (0.89)
EV/EBITDA
0.00 0.00 2.74 3.00
EV/FCF
(0.63) (0.75) (1.07) (0.71)
Current Ratio
2.19 2.49 2.86 3.96
Net Debt/EBITDA
7.94 10.18 47.76 19.62
Debt/Equity
0.73 0.84 0.18 0.17
Earnings Yield
(12.45%) (2.19%) 137.63% 106.54%
Free Cash Flow Yield
(104.20%) (102.44%) 135.00% 88.24%
Free Cash Flow per Share
(0.22) (0.45) 6.46 (1.87)
Book value per Share
2.39 2.23 6.42 6.48
Free Cash Flow
(6.11) (12.54) 203.85 (59.36)
EV/EBIT
0.00 0.00 2.29 2.09
Other line items

Show all line items

Columns are period end dates